# Women's Cancer Study Group GmbH: Phase 3 study closed enrollment, 1684 enrolled (Breast Cancer Female)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Women's Cancer Study Group GmbH |
| Sponsor type | Academic and hospital |
| Study | Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC |
| NCT ID | NCT04055493 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Breast Cancer Female |
| Intervention types | drug |
| Target enrollment | 1684 |
| Site countries | Germany |
| Posted | 2019-08-13 |
| Planned start | 2019-07-02 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-09 |
| Last update posted | 2026-10-09 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 1684 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04055493). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.